# PhaseV Trials

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/phasev-trials

- Industry: Software
- Headquarters: Tel Aviv, Israel
- Website: www.phasevtrials.com
- Total disclosed funding: $65M
- Latest round: Series A (May 13, 2025)
- Investors on record: 6

## About

Based in Tel Aviv, Israel, and co-founded by Raviv Pryluk (CEO), Elad Berkman (CTO), and Dan Goldstaub in 2023, PhaveV Trials Ltd. operates as a provider of machine learning (ML) technology for adaptive clinical trial design and closed-loop execution. In May 2025, PhaseV Trials Ltd. raised USD 50 million in series A funding co-led by new investors Accel and Insight Partners, with participation from returning investors Viola Ventures, EXOR and LionBird. The company is dedicated to developing technologies, statistical methods, and ML-based platforms for adaptive clinical trial design and execution. Their approach is built on the principles of Exploration-Exploitation with Multi-Arm-Bandit, real-time optimization with Modern Software, and detecting hidden signals with Causal-ML. Additionally, PhaseV leverages ML to provide data-driven, actionable clinical insights at any point during a trial and provide recommendations for optimal trial designs. The company also helps increase success rete by optimizing the use of available data with advanced statistical methods, offering optimal resource allocation, and maximizing benefits to patients. The company will use the May 2025 funding for further development and expand its market reach.

## Funding rounds

- Series A, May 13, 2025, $50M — Accel, Viola Ventures, Insight Partners, EXOR, LionBird
- Seed, Oct 24, 2023, $15M — EXOR, Viola Group, LionBird

## Investors

- EXOR — Seed, Series A
- Viola Group (https://capitalatlas.ai/funds/viola-group) — Seed
- LionBird (https://capitalatlas.ai/funds/lionbird) — Seed, Series A
- Accel (https://capitalatlas.ai/funds/accel) — Series A
- Viola Ventures — Series A
- Insight Partners (https://capitalatlas.ai/funds/insight-partners) — Series A